Compile Data Set for Download or QSAR
maximum 50k data
Found 782 with Last Name = 'fortanet' and Initial = 'jg'
TargetSH2B adapter protein 2(Human)
Novartis

US Patent
LigandPNGBDBM484440(US10934285, Example 24)
Affinity DataIC50:  1nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.003-100 μM) was monitored using an assay in which 0.5 nM of ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSH2B adapter protein 2(Human)
Novartis

US Patent
LigandPNGBDBM484457(US10934285, Example 43)
Affinity DataIC50:  1.5nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.003-100 μM) was monitored using an assay in which 0.5 nM of ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSH2B adapter protein 2(Human)
Novartis

US Patent
LigandPNGBDBM484469(US10934285, Example 55)
Affinity DataIC50:  2.80nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.003-100 μM) was monitored using an assay in which 0.5 nM of ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSH2B adapter protein 2(Human)
Novartis

US Patent
LigandPNGBDBM484472(US10934285, Example 59)
Affinity DataIC50: <3nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.003-100 μM) was monitored using an assay in which 0.5 nM of ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSH2B adapter protein 2(Human)
Novartis

US Patent
LigandPNGBDBM484421(US10934285, Example 5)
Affinity DataIC50:  3nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.003-100 μM) was monitored using an assay in which 0.5 nM of ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM408072(US10336774, Example 57)
Affinity DataIC50:  3nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phorphorylated peptides to its Src Homology 2 (SH2) domains. The latter activation st...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSH2B adapter protein 2(Human)
Novartis

US Patent
LigandPNGBDBM484466(US10934285, Example 52)
Affinity DataIC50:  3nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.003-100 μM) was monitored using an assay in which 0.5 nM of ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSH2B adapter protein 2(Human)
Novartis

US Patent
LigandPNGBDBM484461(US10934285, Example 47)
Affinity DataIC50:  3nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.003-100 μM) was monitored using an assay in which 0.5 nM of ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM408094(US10336774, Example 88)
Affinity DataIC50:  4nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phorphorylated peptides to its Src Homology 2 (SH2) domains. The latter activation st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM408096(US10336774, Example 90)
Affinity DataIC50:  4nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phorphorylated peptides to its Src Homology 2 (SH2) domains. The latter activation st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM408075(US10336774, Example 60)
Affinity DataIC50:  4nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phorphorylated peptides to its Src Homology 2 (SH2) domains. The latter activation st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM408073(US10336774, Example 58)
Affinity DataIC50:  4nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phorphorylated peptides to its Src Homology 2 (SH2) domains. The latter activation st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSH2B adapter protein 2(Human)
Novartis

US Patent
LigandPNGBDBM484467(US10934285, Example 53)
Affinity DataIC50:  4.40nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.003-100 μM) was monitored using an assay in which 0.5 nM of ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSH2B adapter protein 2(Human)
Novartis

US Patent
LigandPNGBDBM484429(US10934285, Example 13)
Affinity DataIC50:  4.60nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.003-100 μM) was monitored using an assay in which 0.5 nM of ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSH2B adapter protein 2(Human)
Novartis

US Patent
LigandPNGBDBM484422(US10934285, Example 6)
Affinity DataIC50:  5nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.003-100 μM) was monitored using an assay in which 0.5 nM of ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM408086(US10336774, Example 77)
Affinity DataIC50:  5nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phorphorylated peptides to its Src Homology 2 (SH2) domains. The latter activation st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSH2B adapter protein 2(Human)
Novartis

US Patent
LigandPNGBDBM484439(US10934285, Example 23)
Affinity DataIC50:  5nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.003-100 μM) was monitored using an assay in which 0.5 nM of ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSH2B adapter protein 2(Human)
Novartis

US Patent
LigandPNGBDBM484430(US10934285, Example 14)
Affinity DataIC50:  5.90nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.003-100 μM) was monitored using an assay in which 0.5 nM of ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSH2B adapter protein 2(Human)
Novartis

US Patent
LigandPNGBDBM484423(US10934285, Example 7)
Affinity DataIC50:  6nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.003-100 μM) was monitored using an assay in which 0.5 nM of ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSH2B adapter protein 2(Human)
Novartis

US Patent
LigandPNGBDBM484419(US10934285, Example 3)
Affinity DataIC50:  6nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.003-100 μM) was monitored using an assay in which 0.5 nM of ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM408058(US10336774, Example 43)
Affinity DataIC50:  6nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phorphorylated peptides to its Src Homology 2 (SH2) domains. The latter activation st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSH2B adapter protein 2(Human)
Novartis

US Patent
LigandPNGBDBM484426(US10934285, Example 10)
Affinity DataIC50:  6nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.003-100 μM) was monitored using an assay in which 0.5 nM of ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSH2B adapter protein 2(Human)
Novartis

US Patent
LigandPNGBDBM484451(US10934285, Example 37)
Affinity DataIC50:  6nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.003-100 μM) was monitored using an assay in which 0.5 nM of ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSH2B adapter protein 2(Human)
Novartis

US Patent
LigandPNGBDBM484470(US10934285, Example 56)
Affinity DataIC50:  6.60nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.003-100 μM) was monitored using an assay in which 0.5 nM of ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSH2B adapter protein 2(Human)
Novartis

US Patent
LigandPNGBDBM484418(US10934285, Example 2)
Affinity DataIC50:  7nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.003-100 μM) was monitored using an assay in which 0.5 nM of ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSH2B adapter protein 2(Human)
Novartis

US Patent
LigandPNGBDBM484425(US10934285, Example 9)
Affinity DataIC50:  7nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.003-100 μM) was monitored using an assay in which 0.5 nM of ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSH2B adapter protein 2(Human)
Novartis

US Patent
LigandPNGBDBM484459(US10934285, Example 45)
Affinity DataIC50:  7nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.003-100 μM) was monitored using an assay in which 0.5 nM of ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM408078(US10336774, Example 63)
Affinity DataIC50:  7nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phorphorylated peptides to its Src Homology 2 (SH2) domains. The latter activation st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM408057(US10336774, Example 42)
Affinity DataIC50:  7nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phorphorylated peptides to its Src Homology 2 (SH2) domains. The latter activation st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM408067(US10336774, Example 52)
Affinity DataIC50:  7nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phorphorylated peptides to its Src Homology 2 (SH2) domains. The latter activation st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM408076(US10336774, Example 61)
Affinity DataIC50:  7nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phorphorylated peptides to its Src Homology 2 (SH2) domains. The latter activation st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSH2B adapter protein 2(Human)
Novartis

US Patent
LigandPNGBDBM484468(US10934285, Example 54)
Affinity DataIC50:  7.30nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.003-100 μM) was monitored using an assay in which 0.5 nM of ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM492386(US10975080, Example 83)
Affinity DataIC50:  8nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (SH2) domains. The latter activation st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM50530255(CHEMBL4452417 | US10975080, Example 70)
Affinity DataIC50:  8nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (SH2) domains. The latter activation st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM396004(US10308660, Example 105)
Affinity DataIC50:  8nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (SH2) domains. The latter activation st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSH2B adapter protein 2(Human)
Novartis

US Patent
LigandPNGBDBM484432(US10934285, Example 16)
Affinity DataIC50:  8nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.003-100 μM) was monitored using an assay in which 0.5 nM of ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSH2B adapter protein 2(Human)
Novartis

US Patent
LigandPNGBDBM484446(US10934285, Example 32)
Affinity DataIC50:  8nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.003-100 μM) was monitored using an assay in which 0.5 nM of ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM408097(US10336774, Example 91)
Affinity DataIC50:  8nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phorphorylated peptides to its Src Homology 2 (SH2) domains. The latter activation st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM492338(US10975080, Example 36)
Affinity DataIC50:  9nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (SH2) domains. The latter activation st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM492351(US10975080, Example 49)
Affinity DataIC50:  9nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (SH2) domains. The latter activation st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM395996(US10308660, Example 97)
Affinity DataIC50:  9nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (SH2) domains. The latter activation st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM408063(US10336774, Example 48)
Affinity DataIC50:  9nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phorphorylated peptides to its Src Homology 2 (SH2) domains. The latter activation st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM408071(US10336774, Example 56)
Affinity DataIC50:  9nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phorphorylated peptides to its Src Homology 2 (SH2) domains. The latter activation st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM408093(US10336774, Example 87)
Affinity DataIC50:  9.30nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phorphorylated peptides to its Src Homology 2 (SH2) domains. The latter activation st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM408091(US10336774, Example 86a)
Affinity DataIC50:  10nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phorphorylated peptides to its Src Homology 2 (SH2) domains. The latter activation st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM408092(US10336774, Example 86b)
Affinity DataIC50:  10nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phorphorylated peptides to its Src Homology 2 (SH2) domains. The latter activation st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM408098(US10336774, Example 92)
Affinity DataIC50:  10nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phorphorylated peptides to its Src Homology 2 (SH2) domains. The latter activation st...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSH2B adapter protein 2(Human)
Novartis

US Patent
LigandPNGBDBM484431(US10934285, Example 15)
Affinity DataIC50:  10nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.003-100 μM) was monitored using an assay in which 0.5 nM of ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSH2B adapter protein 2(Human)
Novartis

US Patent
LigandPNGBDBM484438(US10934285, Example 22)
Affinity DataIC50:  10nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.003-100 μM) was monitored using an assay in which 0.5 nM of ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSH2B adapter protein 2(Human)
Novartis

US Patent
LigandPNGBDBM484447(US10934285, Example 33)
Affinity DataIC50:  10nMAssay Description:The inhibition of SHP2 by compounds of the invention (concentrations varying from 0.003-100 μM) was monitored using an assay in which 0.5 nM of ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 782 total ) | Next | Last >>
Jump to: